|
Market Data
Guardant Health Inc
Guardant Health is a precision oncology company specializing in blood and tissue-based tests designed to improve cancer care. The company's core offering, the Guardant360 platform, provides comprehensive genomic profiling, including liquid biopsy and tissue-based tests, to inform treatment decisions. These tests, like Guardant360 CDx and Guardant Reveal, are utilized across the cancer care continuum, from initial diagnosis to monitoring treatment response and detecting recurrence. Guardant Health also offers advanced research tools like GuardantINFINITY and GuardantINFORM, supporting advancements in cancer therapy development. With its headquarters in Palo Alto, California, the company's integrated approach aims to provide actionable insights for both clinical and biopharmaceutical customers.
GH is currently trading at $91.93, giving Guardant Health Inc a market cap of 11.85B. Today's range spans $85.32–$91.92, with shares opening at $86.64 and moving up $1.57 (1.7%) from the prior close. DailyIQ's technical score sits at 64/100 (HOLD) with a news sentiment reading of 49/100.
Over the past year GH has traded between $36.36 and $120.74 - the current price is +152.8% off the 52-week low and -23.9% from the high. 36 analysts cover the stock with a Buy consensus and a mean 12-month target of $128.36 (range $90.00–$180.00), implying upside of +39.6%.
GH is in a holding pattern - 64/100 technical score, HOLD signal, price at $91.93 (in the middle of its 52-week range), sentiment neutral at 49/100. At 11.85B in Healthcare market cap, HOLD phases like this are where the thesis is re-evaluated and position sizing decisions get made by both longs and shorts. Annual range: $36.36–$120.74. The next catalyst, not the current setup, determines the exit from this range.
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $-0.47 | - | - |
| Q4'25 | $-0.72 | $-0.50 | +30.1% |
| Q3'25 | $-0.49 | $-0.39 | +20.3% |
| Q2'25 | $-0.51 | $-0.44 | +14.5% |
| Q1'25 | $-0.59 | $-0.49 | +17.0% |
| Q4'24 | $-0.50 | $-0.62 | -23.1% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $279M | - | - |
| Q4'25 | $279M | $281M | +0.9% |
| Q3'25 | - | $265M | - |
| Q2'25 | - | $232M | - |
| Q1'25 | - | $203M | - |
| Q4'24 | - | $202M | - |
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).